Escala Medical is developing the first repair device for the treatment of pelvic organ prolapse (POP) based on a nonsurgical, incision-free, mesh-free repair approach.
Escala’s novel system presents a long-overdue repair option for women with mild to moderate POP. Escala’s approach mirrors a gold standard surgery-based repair to fixate the vaginal apex to the sacrospinous ligament (SSL) in a safe, quick outpatient procedure.
Founded: December 2014
Stage: Business development
Investor: The Trendlines Group
IP: 1 National phase (U.S., EU, China, Brazil); 1 provisional
In the media: “First-ever incision-free fix for pelvic organ prolapse” (Israel21c)
POP is a clinical condition that affects millions of women worldwide. Associated with physical, psychological, and sexual problems, POP has a significant impact on quality of life. Treatment options are limited.
Surgeons specializing in POP repair are in immediate need of minimally invasive solutions that provide permanent relief of symptoms for the large number of women who are reluctant to use pessaries or undergo surgery.
More than 3.3 million women in the United States are diagnosed with POP. By 2050, it is estimated that the incidence of women with POP will increase by 46%. About 20% undergo surgery for POP (or UI) before the age of 80. Approximately 400,000 surgical repair procedures for POP are performed annually at an estimated direct cost of $1.4 billion.
Escala Medical believes its repair system will increase market potential as a solution for women who may be poor surgical candidates or are reluctant to undergo surgery. The Company estimates the U.S. market opportunity to exceed $600 million.
Major players in the surgical field include Ethicon, Bard, AMS (Endo), Boston Scientific, Coloplast, and Mentor.
Portable, automatic system for peritoneal dialysis
Device for treating ischemic stroke
Anastomotic closure device for laparoscopic bowel resection
Miniature screwless spine fusion implant
Noninvasive monitoring for the diagnosis of heart failure